Genetic Technologies Limited(GENE.US)

Didi 3Q25 Quick Interpretation: In early November, Didi updated the market with guidance on its 3Q performance, mainly mentioning two issues: 1. The investment in the food delivery business in Brazil (to gain a first-mover advantage over Meitu Keeta) will lead to a significant expansion of losses in overseas business; 2. The guidance also indicated that domestic subsidies and other investments would be concentrated in the second half of the year, resulting in a decline in the domestic business's adj. EBITA profit margin compared to the high point in the first half.As this unfavorable guidance was digested by the market, Didi's stock price subsequently retreated by nearly 20%. The actual performance this quarter was largely in line with the previous guidance, with Bloomberg's consensus expectations being somewhat high due to untimely updates, while major banks have made corresponding adjustments. Therefore, overall, Didi's performance this season was expectedly poor.Specifically:1) In terms of core growth indicators, the domestic travel segment's GTV grew by approximately 10% year-on-year, slightly slowing down by about 2 percentage points quarter-on-quarter. The domestic business growth remains generally stable and largely in line with expectations. Meanwhile, the GTV growth rate of overseas business significantly increased to 31%, reflecting that the overseas investment indeed accelerated business growth, and it was notably higher than Bloomberg's consensus expectations.2) In terms of profit, the domestic business adj. EBITA profit was 2.98 billion, slightly higher than the November guidance of 2.7-2.8 billion. However, the trend shows that this quarter's profit margin fell significantly from over 4% in the first two quarters of this year (based on GTV) to 3.5% this quarter, indicating a considerable decline. Dolphin Research preliminarily judges that this is more due to the drag of weakening overall domestic ride-hailing demand (macro factors), while Didi's competitive landscape remains stable or further improved.3) The overseas business's loss this quarter expanded significantly to nearly 1.8 billion, with the loss rate doubling quarter-on-quarter to 5.6%, which is generally in line with the updated expectations of major banks. As mentioned earlier, this is mainly due to the impact of investment in Brazil's food delivery. $DiDi(DIDIY.US)

Investors bet on newer technology and indications for CGTs

Investors are increasingly focusing on novel technologies in the cell and gene therapy (CGT) sector, particularly in vivo CAR-T therapies. Recent high-profile acquisitions include Bristol Myers Squibb's purchase of Orbital Therapeutics for $1.5bn and Gilead Sciences' acquisition of Interius BioTherapeutics for $350m. Despite enthusiasm, in vivo gene therapy is still in its early stages with limited human data. Safety, scalability, and manufacturing capabilities are key investment considerations. Experts see potential in expanding CGTs beyond oncology, with ophthalmology highlighted as a promising area.

“All Genetic Diseases Could be Cured within a Decade”, Hears Dubai Future Forum

At the Dubai Future Forum 2025, Dr. Trevor Martin of Mammoth Biosciences predicted that all genetic diseases could be cured within a decade due to advances in gene editing. The forum also discussed AI's role in commerce, the potential discovery of extraterrestrial life, and shifts in global energy production. Mastercard completed an AI-agent commerce transaction, and solar energy surpassed nuclear energy production. The forum highlighted the need for diverse genomic data and announced the UAE's plan for an Antarctic research base.

19:00 ET The World's First Gene-Editing Therapy Targeting APOC3 for Hyperlipidemia

CorrectSequence Therapeutics has announced the successful completion of dosing for the first patient in its Investigator-Initiated Trial of CS-121, a gene-editing therapy targeting APOC3 for chylomicronemia and hypertriglyceridemia. The patient, who had a history of extremely high triglyceride levels, showed significant improvement with no adverse effects following treatment. CS-121 utilizes transformer Base Editing technology to precisely edit the APOC3 gene, aiming for a one-time treatment with lifelong efficacy. This marks a significant advancement in the treatment of severe hyperlipidemia.

Japanese Study Finds Childhood Trauma Leaves Marks On DNA

A study by Professors Shota Nishitani, Akemi Tomoda, and Masataka Nagao reveals that childhood abuse or neglect alters gene function, leaving biological traces that impact brain structure. The research identified four key DNA methylation sites linked to mistreatment, particularly affecting the FOXP1 gene, which regulates brain development and emotional control. The findings suggest trauma can mimic effects seen in autism, influencing memory and emotional responses. The researchers developed a methylation risk score to objectively identify childhood trauma based on DNA changes.